Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lemuteporfin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LTS/Vehicle | EXPERIMENTAL | Within subject control study |
| Name | Type | Description |
|---|---|---|
| Lemuteporfin | DRUG | lemuteporfin topical solution, 1% |
Inclusion Criteria: * Stage 1 only: healthy subjects * Stage 1-4: male or female subjects age 18 years or older * Stage 2: subjects with sebum excretion rate of 4 or higher on forehead * Stage 2-4: subjects with at least 2 inflammatory acne lesions on the forehead * Stage 3-4: subjects with sebum e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE2 | Acne mRNA vaccine |
| Sagimet Biosciences Inc. Class A | SGMT | 2 | PHASE3 | Denifanstat, TVB-3567 |
| Hoth Therapeutics, Inc. | HOTH | 1 | PHASE2 | HT-001 |
Lemuteporfin is being studied for the treatment of acne. It is a small molecule dermatology asset that Eli Lilly and Company has taken into Phase 1 clinical development. It has not been approved for any use, and the only recorded clinical study in acne has been completed.
Lemuteporfin is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor associated with the drug's clinical program in dermatology, where the asset has reached Phase 1 testing for acne.
Lemuteporfin is in Phase 1 development. One Phase 1/2 study has been run and it is now completed, with no active trials currently listed. The program enrolled 129 participants in total, and the drug remains investigational rather than approved.
Lemuteporfin has been evaluated in a single registered study, NCT01490736, titled a Phase 1/2 sequentially staged safety study in healthy subjects and subjects with mild acne. That trial was completed, enrolled 129 participants, was double blind, and was conducted in Canada.
No. Lemuteporfin is an investigational small molecule and has not been approved for acne or any other indication. Its development has reached Phase 1, and the one completed study, NCT01490736, was a safety-focused trial rather than a pivotal registration program.
The completed trial, NCT01490736, was a Phase 1/2 sequentially staged safety study in healthy volunteers and participants with mild acne. It enrolled 129 people aged 18 years and older of any sex, used a double-blind design without a control arm, and was run in Canada.